Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) EBT (2016 - 2025)

Historic EBT for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.4 million.

  • Spero Therapeutics' EBT rose 5759.0% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.7 million, marking a year-over-year decrease of 67672.08%. This contributed to the annual value of -$68.6 million for FY2024, which is 33389.11% down from last year.
  • Per Spero Therapeutics' latest filing, its EBT stood at -$7.4 million for Q3 2025, which was up 5759.0% from -$1.7 million recorded in Q2 2025.
  • Spero Therapeutics' 5-year EBT high stood at $55.5 million for Q4 2023, and its period low was -$30.1 million during Q1 2022.
  • Its 5-year average for EBT is -$10.0 million, with a median of -$13.9 million in 2025.
  • Its EBT has fluctuated over the past 5 years, first surged by 20021.88% in 2022, then tumbled by 166941.06% in 2024.
  • Quarter analysis of 5 years shows Spero Therapeutics' EBT stood at -$27.4 million in 2021, then soared by 200.22% to $27.5 million in 2022, then soared by 101.91% to $55.5 million in 2023, then crashed by 137.29% to -$20.7 million in 2024, then skyrocketed by 64.32% to -$7.4 million in 2025.
  • Its EBT was -$7.4 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$13.9 million in Q1 2025.